Prevalence of antimicrobial resistance in Helicobacter pylori isolates from Iran

被引:0
作者
Sirous, M. [1 ,2 ]
Mehrabadi, Jalil F.
Daryani, N. E. [3 ]
Eshraghi, S. [1 ,2 ]
Hajikhani, S. [1 ,2 ]
Shirazi, M. H. [1 ,2 ]
机构
[1] Univ Tehran Med Sci, Sch Publ Hlth, Dept Pathobiol, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Publ Hlth, Publ Hlth Res Inst, Tehran, Iran
[3] Univ Tehran Med Sci, Imam Khomeini Hosp, Dept Gastroenterol, Tehran, Iran
来源
AFRICAN JOURNAL OF BIOTECHNOLOGY | 2010年 / 9卷 / 36期
关键词
Helicobacter pylori; antimicrobial resistance; MIC; ANTIBIOTIC-RESISTANCE; TRIPLE THERAPY; ULCER DISEASE; SUSCEPTIBILITY; METRONIDAZOLE; ERADICATION; INFECTION; MANAGEMENT; DIFFUSION; EFFICACY;
D O I
暂无
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Helicobacter pylori, a gram negative bacterium is capable of being resistant to a wide spectrum of antimicrobial drugs. The prevalence of antibiotic resistance in H. pylori strains differs amongst distinct geographical areas and has increased worldwide. Therefore, information concerning the prevalence of antimicrobial-resistant H. pylori strains is important in predicting therapeutic response. In this study, drug susceptibility of H. pylori in patients was investigated in Laleh hospital, Tehran, Iran from 2007 - 2008. 104 antral biopsies of patients with non ulcer dyspepsia and peptic ulcer were cultured. Susceptibility patterns were determined by disk diffusion method. Minimum inhibitory concentration (MIC) was performed for resistant isolates of H. pylori. In our study, 51.5% of clinical isolates showed resistance to metronidazole. All of the isolates were sensitive to other antibiotic disks including clarithromycin, amoxicillin, tetracycline and furazolidone. MIC was determined as 16 mu g/ml in 5.8% and 32 mu g/ml in 94.1% of isolates for metronidazole resistance isolates. The results indicated that the major drug resisted by H. pylori is metronidazole and it should be considered when recommending drugs to patients in this region.
引用
收藏
页码:5962 / 5965
页数:4
相关论文
共 21 条
  • [1] Treatment of Helicobacter pylori infection
    Cavallaro, Lucas G.
    Egan, Brian
    O'Morain, Colm
    Di Mario, Francesco
    [J]. HELICOBACTER, 2006, 11 : 36 - 39
  • [2] Assessment of metronidazole susceptibility in Helicobacter pylori: Statistical validation and error rate analysis of breakpoints determined by the disk diffusion test
    Chaves, S
    Gadanho, M
    Tenreiro, R
    Cabrita, J
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 1999, 37 (05) : 1628 - 1631
  • [3] Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands
    Debets-Ossenkopp, YJ
    Herscheid, AJ
    Pot, RGJ
    Kuipers, EJ
    Kusters, JG
    Vandenbroucke-Grauls, CMJE
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (04) : 511 - 515
  • [4] NITROIMIDAZOLE DRUGS - ACTION AND RESISTANCE MECHANISMS .1. MECHANISMS OF ACTION
    EDWARDS, DI
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1993, 31 (01) : 9 - 20
  • [5] Helicobacter pylori culture and antimicrobial resistance in Iran
    Fallahi, Gholam-Hossein
    Maleknejad, Shohreh
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2007, 74 (02) : 127 - 130
  • [6] Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease
    Hawkey, CJ
    Atherton, JC
    Treichel, HC
    Thjodleifsson, B
    Ravic, M
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (08) : 1065 - 1074
  • [7] Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan
    Hu, Chi-Tan
    Wu, Chao-Chuan
    Lin, Chih-Yung
    Cheng, Chuan-Chu
    Su, Siou-Cing
    Tseng, Yi-Hsiung
    Lin, Nien-Tsung
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2007, 22 (05) : 720 - 723
  • [8] *IARC, 1994, IARC MONOGRAPH EV CA
  • [9] Helicobacter pylori and the risk and management of associated diseases: Gastritis, ulcer disease, atrophic gastritis and gastric cancer
    Kuipers, EJ
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1997, 11 : 71 - 88
  • [10] Second-line treatment for failure to eradicate Helicobacter pylori:: a randomized trial comparing four treatment strategies
    Lamouliatte, H
    Mégraud, F
    Delchier, JC
    Bretagne, JF
    Courillon-Mallet, A
    De Korwin, JD
    Fauchère, JL
    Labigne, A
    Fléjou, JF
    Barthelemy, P
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (08) : 791 - 797